These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9519354)

  • 21. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853.
    Newling DW; Denis L; Vermeylen K
    Cancer; 1993 Dec; 72(12 Suppl):3793-8. PubMed ID: 8252492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group.
    Keuppens F; Whelan P; Carneiro de Moura JL; Newling D; Bono A; Denis L; Robinson M; Mahler C; Sylvester R; De Pauw M
    Cancer; 1993 Dec; 72(12 Suppl):3863-9. PubMed ID: 8252505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Oneto F; Martorana G; Giuliani L; Delli Ponti U; Petracco S; Cortellini P
    Eur Urol; 1990; 18 Suppl 3():48-53. PubMed ID: 2151277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning.
    Glass TR; Tangen CM; Crawford ED; Thompson I
    J Urol; 2003 Jan; 169(1):164-9. PubMed ID: 12478127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
    Iversen P; Christensen MG; Friis E; Hornbøl P; Hvidt V; Iversen HG; Klarskov P; Krarup T; Lund F; Mogensen P
    Cancer; 1990 Sep; 66(5 Suppl):1058-66. PubMed ID: 2144207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
    Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
    Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.
    Roach M; Lu J; Pilepich MV; Asbell SO; Mohiuddin M; Grignon D
    J Urol; 2003 Jan; 169(1):245-50. PubMed ID: 12478146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
    Boccardo F; Rubagotti A; Barichello M; Battaglia M; Carmignani G; Comeri G; Conti G; Cruciani G; Dammino S; Delliponti U; Ditonno P; Ferraris V; Lilliu S; Montefiore F; Portoghese F; Spano G
    J Clin Oncol; 1999 Jul; 17(7):2027-38. PubMed ID: 10561254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group.
    Carvalho AP; de Moura JL; Denis L; Newling D; Smith P; Bono A; Sylvester R; De Pauw M; Ongena P
    Prog Clin Biol Res; 1989; 303():129-43. PubMed ID: 2528736
    [No Abstract]   [Full Text] [Related]  

  • 33. Complete androgen blockade: data from an EORTC 30853 trial.
    Denis L; Keuppens F; Robinson M; Mahler C; Smith P; Pinto de Carvalho AP; Newling D; Bono A; Sylvester R; De Pauw M
    Semin Urol; 1990 Aug; 8(3):166-74. PubMed ID: 2144656
    [No Abstract]   [Full Text] [Related]  

  • 34. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
    Collette L; de Reijke TM; Schröder FH;
    Eur Urol; 2003 Aug; 44(2):182-9; discussion 189. PubMed ID: 12875936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
    Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
    Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.
    Klijn JG; de Voogt HJ; Studer UE; Schröder FH; Sylvester R; De Pauw M
    Cancer; 1993 Dec; 72(12 Suppl):3858-62. PubMed ID: 8252504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996.
    Denis L
    Urology; 1998 May; 51(5A Suppl):50-7. PubMed ID: 9610558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
    Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Schellenger JJ; Kolvenbag GJ
    Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.